New Antibiotics in the Pipeline

Explore the latest developments in antibiotic research and clinical trials presented at ICAAC in this 43-minute conference talk. Gain insights into promising new compounds, innovative drug combinations, and the current state of the antibiotic pipeline. Join Karen Bush from the University of Indiana, Bloomington, and David Shlaes, MD, PhD, from Anti-Infectives Consulting, as they discuss key topics including new agents, company overviews, beta-lactamase inhibitors, strategies for overcoming resistance elements, and the impact on Americans at risk. Delve into discussions on gram-negative infections, antiviral agents, narrow-spectrum antibiotics, and targeted therapies. Understand the challenges and opportunities in developing sustainable solutions to combat antibiotic resistance and learn about the potential future of antimicrobial treatments.

Introduction
New Agents
Company Overview
Betalactamase Inhibitors
Sustainable Overcoming
Resistance Elements
Americans at Risk
Gramnegative Infections
antiviral agents
CSG ID
Narrow spectrum antibiotics
Targeted antibiotics